EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Angiogenesis has become an attractive target for drug therapy because of its key role in
tumor growth. An extensive array of compounds is currently in preclinical development, with …

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression …

Lung cancer is the leading cause of cancer-related death in the United States. Although
tobacco smoking accounts for the majority of lung cancer, approximately 10% of patients …

While cisplatin and carboplatin are active versus most common cancers, epithelial
malignancies are incurable when metastatic. Even if an initial response occurs, acquired …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family
that is abnormally activated in many epithelial tumors. Several mechanisms lead to the …